Veradermics (MANE) Cash & Equivalents (2024 - 2026)

Veradermics (MANE) has 3 years of Cash & Equivalents data on file, last reported at $168.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents changed N/A year-over-year to $168.4 million; the trailing twelve-month figure through Mar 2026 stood at $168.4 million (changed N/A YoY), and the FY2025 full-year result was $21.8 million, down 59.0% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $168.4 million, up from $21.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $168.4 million in Q1 2026 and bottomed at $21.8 million in Q4 2025.
• The 3-year median for Cash & Equivalents is $53.1 million (2024), against an average of $81.1 million.
• Peak annual rise in Cash & Equivalents reached 59.0% in 2025, while the deepest fall reached 59.0% in 2025.
• A 3-year view of Cash & Equivalents shows it stood at $53.1 million in 2024, then plunged by 59.0% to $21.8 million in 2025, then soared by 673.74% to $168.4 million in 2026.
• The last three Cash & Equivalents figures came in at $168.4 million (Q1 2026), $21.8 million (Q4 2025), and $53.1 million (Q4 2024), per Business Quant data.

Peer Comparison